
Geoffrey Lindeman, MD, joint head, Stem Cells and Cancer Division at The Walter and Eliza Hall Institute of Medical Research, discusses a phase 1b dose-escalation and expansion study of the BCL-2 inhibitor venetoclax (Venclexta) combined with tamoxifen in estrogen receptor-positive and BCL-2–positive metastatic breast cancer.




